ProShares Ultra Nasdaq Biotechnology (BIB)
Assets
$93.28M
ProShares
Fee
0.95%
a year
Yield
0.2%
NA
Components
246
top 10: 47%
Performance
The fund's own total return, a year on average over the longer periods; volatility is the yearly standard deviation of its returns.
This year
+37.6%
1 year
+66.6%
3 years
+34.0%
5 years
+5.0%
10 years
+11.3%
Volatility 36.7% over one year, 36.8% over three; Sharpe ratio over three years 0.92.
Largest components
| IQMMProshares Genius Money Market ETF | 19.06% | ||
| GILDGilead Sciences Inc | 5.32% | Healthcare | |
| AMGNAmgen Inc | 5.32% | Healthcare | |
| VRTXVertex Pharmaceuticals Inc | 4.82% | Healthcare | |
| MRNAModerna Inc | 3.72% | Healthcare | |
| REGNRegeneron Pharmaceuticals Inc | 3.31% | Healthcare | |
| RVMDRevolution Medicines Inc | 1.66% | Healthcare | |
| ILMNIllumina Inc | 1.63% | Healthcare | |
| BIIBBiogen Inc | 1.36% | Healthcare | |
| ALNYAlnylam Pharmaceuticals Inc | 1.26% | Healthcare |
Sectors
Healthcare100.0%
Regions
North America97.6%
Europe Developed2.2%
United Kingdom1.9%
Asia Emerging0.1%
Australasia0.1%
Africa/Middle East0.0%
Asia Developed0.0%
Asset classes
Stock US72.9%
Cash28.1%
Other2.7%
Stock non-US-0.7%
About the fund
- Issuer
- ProShares
- Since
- 2010-04-06
- Listed on
- NASDAQ
- ISIN
- US74347R2141
- Turnover
- 23% a year
The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.
From the market data provider's fund data, read 2026-10-19. Returns are the fund's own; past returns say nothing certain about future ones. None of this is advice.